



**11<sup>th</sup> November 2024**

To,  
**BSE Limited**  
P J Towers, Dalal Street  
Fort, Mumbai- 400001.  
Scrip Code : 524518

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai- 400051.  
Scrip Code : KREBSBIO

Dear Sir / Madam,

**Sub: Outcome of Board Meeting - Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September 2024.**

- A. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following:
1. Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September 2024.
  2. Limited Review Report by the Auditors on the Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September 2024.
- B. The Board has also reconstituted the following committees of the Board w.e.f. 11<sup>th</sup> November 2024. The revised Board Committees will now comprise of the following Board Members:

<b>Audit Committee</b>	
Mr. Satish Khemchand Khivsara	Chairman of the Committee/Independent Director
Mr. Raj Kamal Prasad Verma	Independent Director
Mrs. Malati Tangirala	Independent Director
Mr. Jitendra Shah	Managing Director & CEO

<b>Stakeholder Relationship Committee</b>	
Mr. Raj Kamal Prasad Verma	Chairman of the Committee/Independent Director
Mr. Satish Khemchand Khivsara	Independent Director
Dr. R T Ravi	Non Executive Director/ Chairman of the Board
Mr. Avinash Ravi	Non Executive Director



---

<b>Nomination and Remuneration Committee</b>	
Mr. Satish Khemchand Khivsara	Chairman of the Committee/Independent Director
Mr. Raj Kamal Prasad Verma	Independent Director
Mrs. Malati Tangirala	Independent Director
Dr. R T Ravi	Non Executive Director/ Chairman of the Board

The Meeting of the Board of Directors commenced at 12:00 noon and concluded at 1:30 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully

For **Krebs Biochemicals and Industries Limited**

**Rakesh R. Kalbate**

Company Secretary & Compliance Officer

ACS-66666

Encl.: a/a.

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30,2024

(Rs. In lacs)


Sr.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	1,285.52	1,288.90	1,489.01	2,574.42	2,547.14	5042.15
2	Other Income	8.62	3.35	17.42	11.97	21.17	45.13
3	<b>Total Income (1+2)</b>	<b>1,294.14</b>	<b>1,292.25</b>	<b>1,506.43</b>	<b>2,586.39</b>	<b>2,568.31</b>	<b>5,087.28</b>
4	<b>Expenses</b>						
	a) Cost of Material Consumed	103.42	37.29	62.79	140.71	259.42	543.17
	b) Purchase of Stock in Trade	-	3.65	-	3.65	-	8.63
	c) Changes in Inventories of Finished goods, Work-In-Progress	138.70	84.82	142.59	223.52	(17.51)	106.93
	d) Employee Benefits Expenses	439.12	424.90	408.89	864.02	815.27	1,647.41
	e) Finance Costs	142.47	131.81	113.41	274.28	223.14	468.94
	f) Depreciation and Amortisation Expense	171.23	169.05	171.08	340.28	336.40	676.63
	g) Other Expenses	875.28	957.85	964.79	1,833.13	1,842.00	3,608.41
	<b>Total Expenses (4)</b>	<b>1,870.22</b>	<b>1,809.36</b>	<b>1,863.56</b>	<b>3,679.59</b>	<b>3,458.73</b>	<b>7,060.12</b>
5	<b>Profit / (Loss) before exceptional items and tax (3-4)</b>	<b>(576.08)</b>	<b>(517.11)</b>	<b>(357.13)</b>	<b>(1,093.20)</b>	<b>(890.42)</b>	<b>(1,972.84)</b>
6	Exceptional Items:	-	-	-	-	-	-
7	<b>Profit / (Loss) before Tax (5 + 6)</b>	<b>(576.08)</b>	<b>(517.11)</b>	<b>(357.13)</b>	<b>(1,093.20)</b>	<b>(890.42)</b>	<b>(1,972.84)</b>
8	<b>Tax Expense</b>						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	<b>Profit / (Loss) for the period from Continuing Operations (7+8)</b>	<b>(576.08)</b>	<b>(517.11)</b>	<b>(357.13)</b>	<b>(1,093.20)</b>	<b>(890.42)</b>	<b>(1,972.84)</b>
10	<b>Other Comprehensive Income</b>						
	i) Items that will not be reclassified to profit or Loss	-	-	-	-	-	(2.60)
	ii) Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
	iii) Items that will be reclassified to profit or Loss	-	-	-	-	-	-
	iv) Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-	-
	<b>Other Comprehensive Income (Net of Tax)</b>						<b>(2.60)</b>
11	<b>Total Comprehensive Income for the period(9+10)</b>	<b>(576.08)</b>	<b>(517.11)</b>	<b>(357.13)</b>	<b>(1,093.20)</b>	<b>(890.42)</b>	<b>(1,975.44)</b>
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	(15,182.81)
14	<b>Earning Per Share (of Rs.10/- each) (not Annualised)</b>						
	a) Basic	(2.67)	(2.40)	(1.66)	(5.07)	(4.13)	(9.16)
	b) Diluted	(2.67)	(2.40)	(1.66)	(5.07)	(4.13)	(9.16)
15	<b>Net Worth (including Retained Earnings)</b>						<b>(11,921.67)</b>

**Notes:**

- The above unaudited standalone financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on November 11, 2024.
- The Statutory Auditors have carried out Limited Review of the aforesaid results and have issued their "Unmodified Report" thereon.
- The above financial results are prepared in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended).
- Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.

Place: Mumbai

Date: November 11, 2024



*Jitendra Shah*  
Jitendra Shah  
Managing Director  
DIN : 09377846

## KREBS BIOCHEMICALS &amp; INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031


## Unaudited Standalone Statement of Assets and Liabilities as at September 30,2024

(Rs. In Lacs)

Particulars	As at 30.09.2024 Unaudited	As at 31.03.2024 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
(a)Property, Plant and Equipment	14,652.73	14,930.06
(b)Capital Work-In-Progress	65.86	15.57
(c)Other Intangible Assets	56.39	65.61
(d)Intangible assets under development	184.71	184.71
(e)Financial Assets	264.33	254.08
(f)Other Non Current Assets	675.74	623.22
<b>Total Non Current Assets</b>	<b>15,899.76</b>	<b>16,073.25</b>
<b>Current Assets</b>		
(a)Inventories	772.67	979.64
(b)Financial Assets		
(i) Trade Receivables	256.54	190.34
(ii) Cash & Cash Equivalents	14.42	13.74
(iii) Other Financial Assets	1,106.13	301.29
(c)Other Current Assets	470.97	259.21
<b>Total Current Assets</b>	<b>2,620.73</b>	<b>1,744.22</b>
<b>Total Assets</b>	<b>18,520.49</b>	<b>17,817.47</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a)Equity Share Capital	2,156.06	2,156.06
(b)Other Equity	(15,170.94)	(14,077.73)
<b>Total Equity</b>	<b>(13,014.88)</b>	<b>(11,921.67)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a)Financial Liabilities		
(i)Borrowings	16,090.00	18,350.00
(ii)Other Financial Liabilities	269.03	400.73
(b)Provisions	305.02	305.02
(c)Other Non Current Liabilities	4,500.00	4,500.00
<b>Total Non Current Liabilities</b>	<b>21,164.05</b>	<b>23,555.75</b>
<b>Current Liabilities</b>		
(a)Financial Liabilities		
(i)Borrowings	4,366.82	992.95
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	119.62	234.75
(b) Total outstanding dues of creditors other than micro and small enterprises	1,625.60	1,662.25
(iii)Other Financial Liabilities	1,500.37	1,400.59
(b)Other Current Liabilities	2,588.31	1,786.66
(c)Provisions	170.60	106.19
<b>Total Current Liabilities</b>	<b>10,371.32</b>	<b>6,183.39</b>
<b>Total Equity and Liabilities</b>	<b>18,520.49</b>	<b>17,817.47</b>

Place:Mumbai

Date: November 11, 2024



*Jitendra Shah*  
 Jitendra Shah  
 Managing Director  
 DIN : 09377846



**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031


Unaudited Standalone Cash Flow Statement for the Half Year Ended September 30,2024.

(Rs. In Lacs)

Particulars	Half Year Ended 30.09.2024 (Unaudited)	Half Year Ended 30.09.2023 (Unaudited)
<b>A. Cash Flow from Operating Activities</b>		
Net Profit before tax and exceptional items	(1,093.20)	(890.42)
<b>Adjustments for:</b>		
Depreciation and Amortisation Expenses	340.28	336.40
Financial Charges	274.28	223.14
<b>Operating Profit before Working Capital Changes</b>	<b>(478.64)</b>	<b>(330.88)</b>
Changes in Working Capital		
(Increase)/Decrease in Inventories	206.97	79.91
(Increase)/Decrease in Trade Receivables	(66.20)	(43.81)
(Increase)/Decrease in Other Financial Assets	(804.85)	(167.35)
(Increase)/Decrease in Other Current Assets	(211.76)	94.85
(Increase)/Decrease in Financial Assets	(10.25)	(6.40)
(Increase)/Decrease in Other Non Current Assets	(52.52)	(41.66)
Increase /(Decrease) in Retirement benefit obligations	10.02	6.07
Increase/(Decrease) in Current Provisions	54.39	42.55
Increase/(Decrease) in Trade Payables	(151.78)	140.29
Increase/(Decrease) in Other financial liabilities	99.78	193.30
Increase/(Decrease) in financial liabilities	(26.13)	(16.98)
Increase/(Decrease) in Other Current Liabilities	801.65	259.94
<b>Cash generated from Operations</b>	<b>(150.69)</b>	<b>540.70</b>
<b>Net Cash Flow from Operating Activities</b>	<b>(629.34)</b>	<b>209.83</b>
(Increase)/Decrease of Property, Plant & Equipment		
Purchase of Property,Plant and Equipment including Capital Work- In- Progress	(104.00)	(567.29)
Proceeds from / (Payment to) Other Financial Liabilities	(131.70)	104.51
<b>B. Cash Flow from Investing Activities</b>	<b>(235.70)</b>	<b>(462.78)</b>
Financial Charges	(274.28)	(223.14)
Receipts of Long-Term borrowings	1,140.00	475.35
<b>C. Cash Flow from Financing Activities</b>	<b>865.72</b>	<b>252.21</b>
<b>Net Increase (Decrease) in Cash and Cash equivalents (A+B+C)</b>	<b>0.68</b>	<b>(0.75)</b>
Cash and Cash equivalents as at the beginning of the year	13.74	8.58
<b>Cash and Cash equivalents at the end of the year</b>	<b>14.42</b>	<b>7.83</b>
<b>Components of Cash &amp; Cash Equivalents:</b>		
Cash in Hand	0.40	0.14
Bank Balance in Current Account	2.19	0.86
Bank Balance in Fixed Deposit Account	11.83	6.83
	<b>14.42</b>	<b>7.83</b>

Place: Mumbai

Date: November 11, 2024



*Jitendra Shah*

Jitendra Shah  
Managing Director  
DIN : 09377846



Independent Auditor's Review Report on the Quarterly Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI(Listing Obligation and Disclosure Requirements)Regulation,2015,as amended

**Review Report to  
The Board of Directors,  
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30<sup>th</sup> September, 2024** (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended(the "Listing Regulations")
- b) The statement, which is the responsibility of the Company's Management and approved by the Board of Directors ,has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place : Mumbai  
Date : 11-11-2024**



**For Bhavani &Co.**  
Chartered Accountants  
Firm Registration No: 012139S

**CA S Kavitha Padmini**  
Partner  
Membership no: 229966  
UDIN: 24229966BKMBMG3546